Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)
- 1 August 2003
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 41 (2) , 227-231
- https://doi.org/10.1016/s0169-5002(03)00189-2
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)Lung Cancer, 2000
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer ProjectJournal of Clinical Oncology, 1999
- EGF receptorThe International Journal of Biochemistry & Cell Biology, 1999